The unfolded protein response (UPR) is a conserved intracellular signaling network activated when misfolded or unfolded proteins accumulate in the endoplasmic reticulum (ER) lumen, a condition termed ER stress. Under normal conditions, the UPR restores proteostasis by reducing protein synthesis, upregulating ER chaperones, and enhancing ER-associated degradation (ERAD). However, when ER stress is chronic or overwhelming—as occurs in neurodegenerative diseases where aggregation-prone proteins accumulate—the UPR shifts from a protective to a pro-apoptotic program, contributing directly to neuronal death. Dysregulated UPR signaling has been documented in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease, making the UPR a central mechanistic node and therapeutic target in neurodegeneration. [@hetz2017]
The UPR represents a fundamentalcellular quality control mechanism that senses the folding environment within the ER lumen and communicates this information to the cytosol and nucleus. The ER lumen contains an extensive network of molecular chaperones, including BiP (GRP78), that assist in protein folding. Under conditions of ER stress where the load of client proteins exceeds folding capacity, BiP becomes sequestered by binding to misfolded proteins, leaving the three ER transmembrane sensors—PERK, IRE1, and ATF6—unmasked to initiate downstream signaling. [@walter2011]
The unfolded protein response (UPR) is a conserved intracellular signaling network activated when misfolded or unfolded proteins accumulate in the endoplasmic reticulum (ER) lumen, a condition termed ER stress. Under normal conditions, the UPR restores proteostasis by reducing protein synthesis, upregulating ER chaperones, and enhancing ER-associated degradation (ERAD). However, when ER stress is chronic or overwhelming—as occurs in neurodegenerative diseases where aggregation-prone proteins accumulate—the UPR shifts from a protective to a pro-apoptotic program, contributing directly to neuronal death. Dysregulated UPR signaling has been documented in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease, making the UPR a central mechanistic node and therapeutic target in neurodegeneration. [@hetz2017]
The UPR represents a fundamentalcellular quality control mechanism that senses the folding environment within the ER lumen and communicates this information to the cytosol and nucleus. The ER lumen contains an extensive network of molecular chaperones, including BiP (GRP78), that assist in protein folding. Under conditions of ER stress where the load of client proteins exceeds folding capacity, BiP becomes sequestered by binding to misfolded proteins, leaving the three ER transmembrane sensors—PERK, IRE1, and ATF6—unmasked to initiate downstream signaling. [@walter2011]
The UPR was initially characterized in yeast in the 1980s, where the IRE1 pathway was found to mediate transcriptional activation of ER chaperones. Subsequent work in mammalian cells identified all three UPR传感器 and revealed their complex, integrated roles in deciding between adaptive and apoptotic outcomes. The Nobel Prize-winning work on ER stress and the UPR has highlighted its fundamental importance in cellular homeostasis, and dysregulation of the UPR is now recognized as a key contributor to numerous human diseases, including neurodegeneration. [@gething1992]
The PERK (EIF2AK3) kinase is one of the three primary ER stress sensors. Under non-stress conditions, PERK is bound by BiP and maintained in an inactive state. Upon ER stress, BiP dissociation activates PERK's kinase domain, allowing it to autophosphorylate and subsequently phosphorylate the eukaryotic translation initiation factor eIF2α at Ser51. This phosphorylation causes a global translation attenuation while paradoxically permitting translation of specific mRNAs containing upstream open reading frames (uORFs), such as ATF4. [@harding2000]
ATF4 is a transcription factor that drives expression of genes involved in amino acid metabolism, antioxidant responses, and autophagy. Under prolonged ER stress, ATF4 alsoupregulates CHOP (DDIT3), a pro-apoptotic transcription factor that promotes cell death through multiple mechanisms. CHOP represses anti-apoptotic Bcl-2 family proteins, induces GADD34 (PPP1R15A) to dephosphorylate eIF2α (creating a negative feedback loop), and promotes oxidative stress. The PERK-CHOP axis is critically important in determining whether cells survive or undergo apoptosis during ER stress. [@novoa2001]
IRE1 (ERN1) is a dual-function protein containing a serine/threonine kinase domain and an endoribonuclease domain. Activation of IRE1 by ER stress causes dimerization and autophosphorylation, which activates its RNase activity. The key substrate of activated IRE1 is XBP1 mRNA, which undergoes unconventional splicing to produce XBP1s (spliced XBP1), a potent transcription factor. [@calfon2002]
XBP1s drives expression of numerous target genes including:
ATF6 (ATF6A) is a type II transmembrane transcription factor that localizes to the ER membrane under non-stress conditions. Upon ER stress, ATF6 translocates to the Golgi apparatus where it is cleaved by proteases S1P and S2P, releasing the cytosolic domain (ATF6f) that functions as a transcription factor. ATF6f activates genes involved in protein folding, ERAD, and lipid biosynthesis, complementing the PERK and IRE1 pathways. [@haze2019]
Mammals express two isoforms, ATF6α (ATF6) and ATF6β (ATF6B), with overlapping but distinct functions. ATF6α is the primary functionally relevant isoform in the UPR, while ATF6β appears to play more of a modulatory role. ATF6 has gained attention as a potential therapeutic target because its activation does not involve the pro-apoptotic outputs of PERK and IRE1, making it potentially safer to pharmacologically enhance.
The three UPR branches do not operate in isolation but are integrated at multiple levels:
The decision point between adaptive and apoptotic UPR outcomes is determined by the intensity and duration of ER stress, the cell's metabolic state, and the balance between pro-survival and pro-death signals from all three branches. [@hetz2023]
ER stress and UPR activation are prominent features of AD pathophysiology: [@ma2013]
PD shows selective vulnerability to ER stress: [@dauer2003]
UPR activation is a consistent finding in ALS: [@saxena2013]
HD shows ER stress involvement: [@orr2002]
FTD, particularly the TDP-43 pathology forms, involves UPR: [@rascovsky2021]
The UPR promotes neuronal death through multiple pathways:
CHOP is the primary executor of UPR-induced apoptosis. Its pro-death functions include: [@gorman2007]
Prolonged IRE1 activation triggers death pathways:
ER stress disrupts calcium homeostasis:
Neurons can also die through non-apoptotic mechanisms:
| Target | Approach | Therapeutic Agent | Status |
|--------|----------|------------------|--------|
| PERK | Inhibition | GSK2656157 | Preclinical |
| IRE1 | Inhibition | MKC8866, 4μ8C | Preclinical |
| eIF2α | Dephosphorylation | ISRIB | Preclinical |
| CHOP | Inhibition | Small molecules | Early development |
| ATF6 | Activation | AAV vectors | Preclinical |
| ER chaperones | Enhancement | Bix, etc. | Clinical trials |
Several clinical approaches target UPR in neurodegeneration:
Clinical biomarkers for UPR include:
| Biomarker | Detection Method | Disease | Clinical Utility |
|-----------|-----------------|---------|------------------|
| CHOP mRNA | qPCR | PD, AD | Disease progression |
| XBP1 splicing | PCR | ALS, PD | Diagnostic |
| BiP/GRP78 | ELISA | Various | Nest Diagnostic |
| Phospho-eIF2α | IHC | Research | Research only |
| ATF6 cleavage | Western blot | Research | Research only |
The ER and mitochondria form close contacts called mitochondria-associated membranes (MAMs), which are critical for calcium signaling and lipid transfer. ER stress disrupts MAMs, leading to:
ER stress activates NF-κB and other inflammatory pathways:
The UPR is part of the broader integrated stress response (ISR), which senses various cellular stresses:
| Agent | Target | Phase | Status | NCT |
|-------|-------|-------|--------|-----|
| TUDCA (Tauroursodeoxycholic acid) | ER stress modulation | Phase II | Completed | NCT0298725 |
| TUDCA | ER stress modulation | Phase III | Recruiting | NCT05677620 |
| Sodium phenylbutyrate/taurursodiol (Relyvrio) | UPR modulation | Phase III | Approved (ALS) | NCT03184449 |
| ISRIB | eIF2B stabilization | Preclinical | - | - |
| GSK2606414 | PERK inhibition | Preclinical | - | - |
| MKC8866 | IRE1 inhibition | Preclinical | - | - |
TUDCA in Neurodegeneration: Tauroursodeoxycholic acid (TUDCA) has been studied in multiple neurodegenerative conditions. The Phase II study in PD (NCT0298725) showed signals of neuroprotective benefit, with larger Phase III trials now recruiting [@sanchez2019]. In ALS, the combination of sodium phenylbutyrate and taurursodiol (Relyvrio) received FDA approval based on Phase III data showing survival benefit.
PERK Inhibitors: GSK2606414 and related PERK inhibitors have shown efficacy in mouse models of prion disease and AD, reducing neuronal loss. However, PERK inhibition can cause pancreatic toxicity due to the essential role of PERK in protein folding in pancreatic beta cells. Second-generation PERK inhibitors with improved selectivity are in development.
IRE1 Modulators: IRE1 inhibitors like MKC8866 reduce both pro-survival (XBP1s) and pro-death (RIDD) activities, making the therapeutic window complex. Selective modulators that promote adaptive XBP1s while inhibiting RIDD are under development.
| Biomarker | Detection Method | Disease | Clinical Utility |
|----------|---------------|---------|---------------|
| CHOP (DDIT3) mRNA | qPCR from blood | AD, PD, ALS | Disease progression marker |
| XBP1 splicing ratio | PCR from PBMCs | ALS, PD | Target engagement |
| BiP/GRP78 (HSPA5) | ELISA (blood/CSF) | AD, PD | Nested diagnostic |
| Phospho-eIF2α (Ser51) | Western blot | Research | Research use only |
| ATF6 cleavage | IHC | Research | Research use only |
| Exosomal UPR markers | Exosome isolation | AD, PD | Emerging biomarker |
Blood-Based Biomarkers: CHOP mRNA levels in peripheral blood mononuclear cells (PBMCs) correlate with disease severity in ALS and PD. The XBP1 splicing ratio provides a functional readouts of IRE1 activity that can be used to assess target engagement in clinical trials. Elevated BiP/GRP78 in CSF has been reported in AD and may serve as a diagnostic marker.
Imaging Biomarkers: While direct imaging of UPR activation is not yet possible, MR spectroscopy can detect elevated hippocampal glutamate in AD, which may reflect impaired protein synthesis due to eIF2α phosphorylation. PET tracers for activated microglia (e.g., TSPO) may indirectly reflect UPR-associated neuroinflammation.
Disease-Modifying Potential: UPR modulators represent a genuinely disease-modifying approach rather than symptomatic treatment. By targeting the core proteostasis dysfunction in neurodegeneration, these agents could potentially slow or halt disease progression rather than merely alleviating symptoms.
Therapeutic Challenges: Several challenges limit UPR-targeted therapy development:
Binding immunoglobulin protein (BiP), also known as glucose-regulated protein 78 (GRP78), is the central ER chaperone that plays a pivotal role in UPR regulation. As a member of the Hsp70 family, BiP possesses ATPase activity and substrate-binding domains that enable it to recognize and fold nascent polypeptides [@lee2014]. Under normal conditions, BiP binds to the luminal domains of PERK, IRE1, and ATF6, maintaining them in an inactive state. During ER stress, BiP preferentially binds to misfolded proteins, releasing the UPR sensors to initiate signaling cascades.
The importance of BiP in neuronal survival cannot be overstated. Multiple studies have demonstrated that BiP overexpression protects neurons against various insults, including amyloid-β toxicity in Alzheimer's disease and mutant α-synuclein in Parkinson's disease [@liu2019]. Conversely, BiP deficiency leads to spontaneous ER stress and neurodegeneration in animal models.
Beyond BiP, the ER lumen contains a comprehensive network of chaperones and folding enzymes:
Dopaminergic neurons in the substantia nigra pars compacta exhibit particular vulnerability to ER stress. This vulnerability stems from multiple factors: their high metabolic demand due to pacemaking activity, the presence of neuromelanin granules that can sequester iron and promote oxidative stress, and the expression of proteins with high aggregation propensity [@dua2023].
In Parkinson's disease, dopaminergic neurons show:
Motor neurons in ALS exhibit pronounced UPR activation, with all three branches consistently engaged:
In Alzheimer's disease, cortical and hippocampal neurons show distinctive UPR patterns:
Several genetic forms of neurodegenerative diseases directly implicate UPR pathways:
Alzheimer's disease:
Transcriptomic analyses of affected brain regions reveal consistent UPR gene signatures:
Recent drug discovery efforts have yielded promising UPR modulators:
PERK inhibitors:
Approaches targeting ER chaperone function:
Given the complexity of UPR dysregulation, combination approaches show promise:
Clinical biomarkers for UPR remain a significant unmet need:
[@lee2014]: [Lee AS. The ER chaperone BIp. Nature Reviews Molecular Cell Biology. 2014;15(8):517-528.](https://doi.org/10.1038/nrm3840)
[@liu2019]: [Liu CY, et al. Role of GRP78/BiP in neuroprotection. Cell Stress and Chaperones. 2019;24(1):17-27.](https://doi.org/10.1007/s12192-018-0094-5)
[@ellgaard2022]: [Ellgaard L, et al. The ER protein folding quality control. Annual Review of Biochemistry. 2022;91:403-424.](https://doi.org/10.1146/annurev-biochem-032620-104513)
[@dua2023]: [Dua P, et al. Dopaminergic neuron vulnerability in Parkinson's disease. Journal of Parkinson's Disease. 2023;13(2):201-216.](https://doi.org/10.3233/JPD-223500)
[@burre2022]: [Burre J, et al. ER stress in patient-derived dopaminergic neurons. Brain. 2022;145(3):1015-1028.](https://doi.org/10.1093/brain/awab430)
[@medinas2022]: [Medinas DB, et al. ALS and the Unfolded Protein Response. Neuron. 2022;110(6):943-956.](https://doi.org/10.1016/j.neuron.2021.12.018)
[@shen2024]: [Shen H, et al. Temporal progression of UPR in Alzheimer's disease. Nature Neuroscience. 2024;27(1):89-101.](https://doi.org/10.1038/s41593-023-01456-8)
[@mounsey2023]: [Mounsey K, et al. Transcriptomic UPR signatures in neurodegenerative disease. Brain Pathology. 2023;33(2):e13124.](https://doi.org/10.1111/bpa.13124)
[@park2024]: [Park HW, et al. Emerging UPR therapeutic targets. Pharmacological Reviews. 2024;76(1):123-165.](https://doi.org/10.1124/pharmrev.123.000890)
[@huang2024]: [Huang K, et al. Exosomal UPR markers. Molecular Neurodegeneration. 2024;19(1):12.](https://doi.org/10.1186/s40035-024-00401-4)
[@sanchez2019]: [Sanchez MG, et al. TUDCA for Parkinson's disease: A randomized controlled trial. Journal of Parkinson's Disease. 2019;9(3):445-454.](https://doi.org/10.3233/JPD-191392)
The following diagram shows the key molecular relationships involving Unfolded Protein Response (UPR) discovered through SciDEX knowledge graph analysis: